Skip to content
BrainsWay logo — Global leader in advanced noninvasive neurostimulation treat...

BrainsWay

Global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Founded 2003 United States Burlington, United States 132 employees Post-IPO Equity Total: $87.00M Biotechnology, Health Care

General Information

Company Name BrainsWay
Founded Year 2003
Location United States Burlington, United States
Employees 132
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with BrainsWay. To contact BrainsWay, visit brainsway.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BrainsWay compare?

A PDF of BrainsWay and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BrainsWay soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company, founded in 2003, is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. With offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. At 23 February 2021, the company secured a $45.20M Post-IPO Equity investment. For more information, visit www.brainsway.com.

Business keywords: Neurostimulation, Deep TMS, Noninvasive treatments, Mental health disorders, FDA-cleared indications, Clinical trials, Brain disorder treatment, Medical devices, Neuromodulation, Neurology, Depression treatment, Obsessive-compulsive disorder treatment, Smoking addiction treatment, Global leader, Patient wellbeing

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $45.20M -
23 Feb 2021
Post IPO Equity ILS30.00M 3
IBI CAPITAL LTD, Phoenix Insurance Company +1
11 Dec 2017
Post IPO Equity Undisclosed -
01 Jan 2015
Post IPO Equity $11.80M 1
Yelin Lapidot Investment House
11 Mar 2014

BrainsWay Alternatives & Competitors

BrainsWay vs
Nexstim
Nexstim Finland

We enable personalized and effective therapies and diagnostics for challenging brain diseases and di...

Post-IPO Debt
52 employees
Biotechnology, Health Care
BrainsWay vs

AI-powered point-of-care EEG revolutionizing seizure management in acute care

Series C
386 employees
Biotechnology, Health Care

FAQ About BrainsWay

Global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
BrainsWay was founded in 2003.
BrainsWay is headquartered in Burlington, United States.
BrainsWay operates in Biotechnology and Health Care. Its work centres on Neurostimulation, Deep TMS, Noninvasive treatments and Mental health disorders.
BrainsWay has approximately 132 employees.
BrainsWay has completed 4 funding rounds, raising a total of $87.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to BrainsWay include Nexstim, Ceribell │ AI-Powered Point-of-Care EEG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BrainsWay and Nexstim are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BrainsWay, https://bouncewatch.com/company/brainsway, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout